We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Type
- ARTG (493)
- Cancellation by sponsor (472)
- Australian Public Assessment Report (AusPAR) (65)
- Prescription medicine registration (41)
- Section 14, TGO91 consent (21)
- Prescription medicine decision summary (19)
- Designation or determination (9)
- Cancellation or suspension (7)
- Prescription medicine evaluation (2)
Date
- 2024 (71)
- 2023 (73)
- 2022 (61)
- 2021 (126)
- 2020 (107)
- 2019 (98)
- 2018 (98)
- 2017 (74)
- 2016 (12)
- 2015 (22)
- 2014 (23)
- 2013 (9)
- 2012 (9)
- 2011 (14)
- 2010 (29)
- 2009 (13)
- 2008 (6)
- 2007 (11)
- 2006 (8)
- 2005 (4)
- 2004 (8)
- 2003 (9)
- 2002 (13)
- 2001 (8)
- 2000 (22)
- 1999 (12)
- 1998 (12)
- 1997 (18)
- 1996 (8)
- 1995 (3)
- 1994 (33)
- 1993 (19)
- 1992 (8)
- 1991 (88)
Results for
"[search-keyword]"
Sponsor content
1129 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Elrexfio has provisional approval for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody and have demonstrated disease progression on the last therapy.
-
Australian Public Assessment Report (AusPAR)Paxlovid has been approved for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled plastic syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection prefilled glass syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 10 micrograms/0.2 mL concentrated suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection single dose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 3 micrograms/0.2 mL concentrated suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 3 micrograms/0.3 mL concentrated suspension for injection multidose vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for COMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection multidose vial.